Impact of Bronchodilator Use on the Prevalence of COPD in Population-Based Samples

The aim of this study was to describe the impact of using bronchodilators on the prevalence of Chronic Obstructive Pulmonary Disease in a population-based survey (Platino study). A cluster sampling of subjects 40 years of age or older, representative of the metropolitan areas of 5 Latin American cities (Sao Paulo, Mexico, Montevideo, Santiago and Caracas) was chosen. Spirometry according to ATS standards was done before and after inhalation of 200 micrograms of salbutamol in 5183 subjects. Prevalences of airflow obstruction were estimated using different criteria, in tests done before and after bronchodilator use, and with reference values for pre- or post-bronchodilator use. Bronchodilator testing reduced the overall prevalence of FEV1/FVC% < 0.70 from 21.7% to 14% (35%). In the group with FEV1/FVC < 0.70 after bronchodilator use, 21% were asymptomatic from the respiratory point of view, and lacked significant adverse exposures. Subjects below the 5th percentile for FEV1/FVC and FEV1/FEV6 were fewer than those with FEV1/FVC < 0.70, especially among the elderly. More subjects are below the 5th percentile of FEV1/FVC and FEV1/FEV6 using reference values for tests after bronchodilator use than using the reference values determined without bronchodilator testing. Testing after bronchodilator use reduces the prevalence of airflow obstruction from 32 to 39% depending on the definition used. In addition, the subjects who were still obstructed after bronchodilator use were the ones who showed more respiratory symptoms and exposure to tobacco and other smokes and dusts, than subjects with reversible obstruction, suggesting an increased specificity for COPD.

[1]  G. Valdivia,et al.  The long-term stability of portable spirometers used in a multinational study of the prevalence of chronic obstructive pulmonary disease. , 2006, Respiratory care.

[2]  A. Gulsvik,et al.  Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. , 2006, Pulmonary pharmacology & therapeutics.

[3]  G. Valdivia,et al.  [Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over]. , 2006, Archivos de bronconeumologia.

[4]  J. Jardim,et al.  Valores de referencia espirométrica en 5 grandes ciudades de Latinoamérica para sujetos de 40 o más años de edad , 2006 .

[5]  A. Gulsvik,et al.  Post-bronchodilator spirometry reference values in adults and implications for disease management. , 2006, American journal of respiratory and critical care medicine.

[6]  K. Weiss,et al.  Spirometry use in clinical practice following diagnosis of COPD. , 2006, Chest.

[7]  N. Pride,et al.  Proposal for a multidimensional staging system for chronic obstructive pulmonary disease: Respir Med 2005;99:1546–54 , 2006 .

[8]  P. Enright.  Does screening for COPD by primary care physicians have the potential to cause more harm than good? , 2006, Chest.

[9]  A. Buist,et al.  Case Definitions for Chronic Obstructive Pulmonary Disease , 2006, COPD.

[10]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[11]  J. Samet,et al.  Spirometry for chronic obstructive pulmonary disease case finding in primary care? , 2005, American journal of respiratory and critical care medicine.

[12]  B. Celli,et al.  Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. , 2005, The American journal of medicine.

[13]  N. Pride,et al.  Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. , 2005, Respiratory medicine.

[14]  Cesar G Victora,et al.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study , 2005, The Lancet.

[15]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[16]  A. Gulsvik,et al.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study , 2005, Thorax.

[17]  A. Gulsvik,et al.  Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[19]  N. Anthonisen,et al.  Bronchodilator response in the lung health study over 11 yrs , 2005, European Respiratory Journal.

[20]  J. Vestbo,et al.  Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness? , 2005, European Respiratory Journal.

[21]  A. Woodcock,et al.  Measuring bronchodilation in COPD clinical trials. , 2005, British journal of clinical pharmacology.

[22]  A. Buist,et al.  The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design , 2005 .

[23]  S. K. Chhabra,et al.  Acute Bronchodilator Response Has Limited Value in Differentiating Bronchial Asthma from COPD , 2005, The Journal of asthma : official journal of the Association for the Care of Asthma.

[24]  T. Wilt,et al.  Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). , 2005, Evidence report/technology assessment.

[25]  C. Victora,et al.  The Platino project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities , 2004, BMC medical research methodology.

[26]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[27]  Christine Jenkins,et al.  Assessing bronchodilator reversibility: agreed standards are urgently needed , 2004, The Medical journal of Australia.

[28]  R. Pellegrino,et al.  Assessment of emphysema in COPD: a functional and radiologic study. , 2004, Chest.

[29]  T. Takishima,et al.  Underdiagnosis and undertreatment of COPD in primary care settings , 2003, Respirology.

[30]  B. Celli,et al.  Population impact of different definitions of airway obstruction , 2003, European Respiratory Journal.

[31]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[32]  J. Izquierdo,et al.  The burden of COPD in Spain: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[33]  A. Rossi,et al.  The burden of COPD in Italy: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[34]  A. Buist,et al.  Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers , 2002, European Respiratory Journal.

[35]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[36]  L. Forkert,et al.  Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. , 2002, Chest.

[37]  L. Forkert,et al.  Evaluation of bronchodilator responses in patients with “irreversible” emphysema , 2001, European Respiratory Journal.

[38]  D. Tashkin,et al.  Underdiagnosis of chronic obstructive pulmonary disease: a rationale for spirometry as a screening tool. , 2001, Canadian respiratory journal.

[39]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[40]  Christine Jenkins,et al.  GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY , 2001 .

[41]  K. P. Van de Woestijne,et al.  Mechanisms for isolated volume response to a bronchodilator in patients with COPD. , 2000, Journal of applied physiology.

[42]  G. Viegi,et al.  Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. , 2000, Chest.

[43]  A. Buist,et al.  Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. , 2000, Chest.

[44]  R. GolpeGómez,et al.  Treatment of COPD in primary care , 2000 .

[45]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[46]  D. Postma,et al.  Lack of correlation between bronchoconstrictor response and bronchodilator response in a population-based study. , 1997, The European respiratory journal.

[47]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[48]  A. Rebuck,et al.  Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? , 1994, Chest.

[49]  D. Postma,et al.  Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. , 1993, Thorax.

[50]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[51]  C. van Weel,et al.  A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. , 1992, The European respiratory journal.

[52]  D. Postma,et al.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. , 1992, Thorax.

[53]  Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. , 1991, The American review of respiratory disease.

[54]  P. Rees,et al.  Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. , 1990, Respiratory medicine.

[55]  A. Buist.  Standardization of spirometry. , 1987, The American review of respiratory disease.